Compare VRTX & NOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | NOC |
|---|---|---|
| Founded | 1989 | 1939 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 80.9B |
| IPO Year | 1991 | N/A |
| Metric | VRTX | NOC |
|---|---|---|
| Price | $448.93 | $650.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 18 |
| Target Price | $501.42 | ★ $643.94 |
| AVG Volume (30 Days) | ★ 1.3M | 905.2K |
| Earning Date | 02-09-2026 | 01-27-2026 |
| Dividend Yield | N/A | ★ 1.48% |
| EPS Growth | N/A | ★ 73.89 |
| EPS | 14.22 | ★ 27.81 |
| Revenue | $11,723,300,000.00 | ★ $40,928,000,000.00 |
| Revenue This Year | $11.01 | $3.05 |
| Revenue Next Year | $8.74 | $5.65 |
| P/E Ratio | $31.97 | ★ $22.49 |
| Revenue Growth | ★ 10.33 | N/A |
| 52 Week Low | $362.50 | $426.24 |
| 52 Week High | $519.68 | $640.90 |
| Indicator | VRTX | NOC |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 70.05 |
| Support Level | $443.12 | $619.68 |
| Resistance Level | $487.52 | $638.84 |
| Average True Range (ATR) | 9.79 | 19.12 |
| MACD | -1.81 | 6.29 |
| Stochastic Oscillator | 14.91 | 93.13 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Northrop Grumman is a diversified defense contractor providing aeronautics, defense, and space systems. The company's aerospace segment produces autonomous and piloted aircraft such as Global Hawk drones and the new B-21 bomber, creates the fuselage for the massive F-35 program, and maintains and upgrades numerous other military aircraft. Defense systems makes artillery and missile ammunition and guidance systems, long-range missiles, and missile defense systems. Mission systems creates and integrates a variety of radar, navigation, and communication systems for avionics, weapons control, and countermeasures on a range of platforms from helicopters to destroyers. Space systems produces satellites, sensors, space structures, and rocket motors.